GenomeDx Biosciences today announced that data presented at the 2015 American Society of Clinical Oncology Annual Meeting demonstrate that the Decipher® Prostate Cancer Classifier is a significant ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced results from the ENZAMET trial presented at the 2026 ASCO Annual ...
Interaction between obesity and vitamin D and testosterone and vitamin D in prostate cancer patients on active surveillance in the PROVENT trial. This is an ASCO Meeting Abstract from the 2026 ASCO ...
A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...
The Prostate Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) scoring system accurately predicted the progression of prostate cancer, with scores of 4-5 linked to 4.53-fold ...
Stage 3 prostate cancer is locally advanced, with tumors extending beyond the prostate but not metastasizing distantly. Diagnosis involves the TNM system, Gleason score, PSA tests, and imaging to ...
Basal-luminal classifiers, such as PAM50, may predict prostate cancer grade progression risk in men with low- to intermediate-risk prostate cancer who are considering active surveillance.
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced results from the ENZAMET trial presented at the 2026 ASCO Annual Meeting. The analysis demonstrates that the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results